Pharvaris Hosts Virtual Investor Event Focused on HAE Treatment
Pharvaris, a late-stage biopharmaceutical company respected for developing innovative oral bradykinin B2 receptor antagonists, is gearing up for a significant virtual investor event. This event will emphasize the pressing needs in the treatment and preventive care of hereditary angioedema (HAE) attacks. Scheduled for Wednesday, October 23, 2024, at 10:00 a.m. ET/16:00 CET, attendees will gain insights into the potential impact of their treatment candidate, deucrictibant, in addressing these needs.
Details of the Upcoming Event
The virtual investor event will provide a comprehensive overview of HAE, an often-debilitating condition characterized by unpredictable swelling episodes. Corporate leaders from Pharvaris will present information regarding market dynamics surrounding HAE, alongside expert views on therapeutic advancements. This informative session aims to inform stakeholders about the evolving landscape of HAE treatment and offer detailed insights into their clinical developments.
Esteemed Speakers Set to Present
Participants can look forward to perspectives from an impressive lineup of speakers, each bringing their expertise to the discussion. Presenters include:
- Michael E. Manning, M.D. from Allergy, Asthma & Immunology Associates, LTD
- Raffi Tachdjian, M.D., MPH from the David Geffen School of Medicine at UCLA
- Berndt Modig, CEO of Pharvaris
- Peng Lu, M.D., Ph.D., CMO of Pharvaris
- Wim Souverijns, Ph.D., CCO of Pharvaris
A live question and answer session will allow investors and interested stakeholders to engage directly with the presenters, providing a platform for addressing specific queries about the advancements in HAE treatment.
Pharvaris’s Commitment to HAE Treatment
Pharvaris is on the forefront of innovation, dedicated to developing effective therapies for individuals suffering from all forms of bradykinin-mediated angioedema. Their efforts focus on creating well-tolerated, easy-to-administer treatment alternatives for both the prevention and acute management of HAE attacks. With positive results emerging from Phase 2 clinical trials, there is considerable optimism surrounding deucrictibant as it enters pivotal Phase 3 studies.
The Future of HAE Management
The company is not just looking to address current treatment gaps in HAE but is also committed to advancing the science behind it. Pharvaris plans to initiate a pivotal Phase 3 study evaluating deucrictibant for the prevention of HAE attacks shortly, demonstrating a proactive approach in the clinical landscape. This dedication positions Pharvaris as a significant player in the HAE treatment market, reflecting their ambitious vision to enhance patients' quality of life.
Frequently Asked Questions
What is the aim of the virtual investor event hosted by Pharvaris?
The event aims to provide insights into the unmet needs in HAE treatment, highlighting the potential of deucrictibant and discussing current market dynamics.
Who are the key speakers at the Pharvaris event?
The event will feature esteemed experts, including Dr. Michael E. Manning, Dr. Raffi Tachdjian, and executives from Pharvaris such as Berndt Modig and Peng Lu.
What topics will be covered during the Pharvaris event?
Topics will include the need for effective HAE treatment options, updates on deucrictibant, and insights on HAE market dynamics.
How can I participate in the Pharvaris investor event?
Registration details can be found on the Pharvaris website, where potential attendees can secure their participation in the virtual event.
What is the current state of research on deucrictibant?
Pharvaris is currently enrolling patients in a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to start a prevention study soon.
